SCA
VRTX icon

Strategic Capital Alternatives’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategic Capital Alternatives’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$2.19M Buy
20,987
+5,012
+31% +$644K 0.46% 66
2015
Q2 		$1.94M Sell
15,975
-3,788
-19% -$477K 0.47% 76
2015
Q1 		$2.33M Buy
19,763
+5,737
+41% +$687K 0.58% 60
2014
Q4 		$1.67M Buy
+14,026
New +$1.58M 0.65% 63

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Strategic Capital Alternatives's VRTX Position: Q3 2015 in Review

Strategic Capital Alternatives increased its Vertex Pharmaceuticals (VRTX) stake by 31% in Q3 2015, buying an estimated $644K and bringing the position to 20,987 shares worth $2.19M. The position accounts for 0.46% of the portfolio, ranked #66.

Strategic Capital Alternatives first reported a position in VRTX in Q4 2014 and has held it in 4 quarters since. The position peaked at $2.33M in Q1 2015. 494 funds tracked by Wall St. Rank hold VRTX as of Q3 2015.

  • Strategic Capital Alternatives held 20,987 shares of Vertex Pharmaceuticals worth $2.19M as of Q3 2015.
  • Strategic Capital Alternatives bought 5,012 Vertex Pharmaceuticals shares in Q3 2015, an estimated $644K.
  • Vertex Pharmaceuticals made up 0.46% of Strategic Capital Alternatives's portfolio in Q3 2015, its #66 holding.
  • Strategic Capital Alternatives first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 4 quarters since.
  • Strategic Capital Alternatives's Vertex Pharmaceuticals position peaked at $2.33M in Q1 2015.
  • 494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.